WP-1 / community of expertise

26 August 2022
Navigating global and national identifiers using IDMP and FHIR

Esther Peelen
Leonora Grandia
Craig Anderson
Giorgio Cangioli
Hugh Glover
Rik Smithies

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299
SOME RULES FOR THE VIRTUAL MEETINGS
Our interactive session:

✓ Everybody is on mute
✓ You post your question in the Q&A facility
✓ When you speak, please keep concise
✓ You may show your approval!

After (and during) the introduction presentations, any UNICOM related question / comment may be shared with Q&A
Asking a question or making a comment: please use the Q&A facility

1. Move the mouse on the screen to have the options bar appearing

2. You then select «Q&A» and write your question
Showing support and providing a comment on a question or answer

You can support a question by clicking the «thumbs up» which moves it up on the list for the presenters.

You can comment on a question or answer to engage in a conversation.

Typing and sending a new question does not retain the context of your comment.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299.
Security

- Security is our priority
- This session is password protected

Recording of this session is made available on UNICOM’s youtube channel [https://www.youtube.com/channel/UCBsNj4B33Q7-50XTXdqAGIg](https://www.youtube.com/channel/UCBsNj4B33Q7-50XTXdqAGIg)

At the end of the virtual session, a questionnaire will be sent to the participants, to help us understand participant’s reactions and needs
Introductions to our esteemed colleagues and today's speakers...

Esther Peelen  Craig Anderson  Giorgio Cangioli  Leonora Grandia

...and our panellist

Hugh Glover  Rik Smithies

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299
Questions in the Q & A facility, please
For feedback, please go to :
https://docs.google.com/forms/d/e/1FAIpQLSdXBLlrrWUmWigmwRIHptID6fD6zeSUkX8MpmLNRehGkIS8FrQ/viewform?usp=pp_url

Thanks for your time
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299
What to expect in this webinar?

► A patient journey
► How IDMP identifiers can bring value to the patient, healthcare professional and national medicinal product dictionary
► IDMP and Gravitate Health
► The importance of having structured data
► What happens on the technical side using HL7 FHIR?
► The perspective of a national medicinal product dictionary
Helen
38 years old

- London, UK
- Business Lawyer
- Diabetic type 1
- Humalog Mix50
International Patient Summary

UK 🇬🇧
Helen
38 years old

Past medication

Monuril
Global PhPID: 0xE857DA8...
Active Subst: Fosfomycin 3g
Strength: 5.63g per portion
Dose form: Oral solution
Route of administration: Oral
MPIID: 387730110000001105
PCID: 387731110000001106
Pharmacy Information System

Global PhPID: 0xE857DA811B4A6F3BD57810C45D2EA1ED

Resources:
- AdministrableProductDefinition
- MedicinalProductDefinition

MPD Product Look-up

NL MPD (UFIS)

Global PhPID: 0xE857DA811B4A6F3BD57810C45D2EA1ED

Search:
[mpd fhir server]/AdministrableProductDefinition? identifier=https://www.who-umc.org/phpid/[PhPID]
&_include=AdministrableProductDefinition:form-of

FCAT May 2022, FHIR 4.6.0
Pharmacy Information System

MPD Product Retrieval

<table>
<thead>
<tr>
<th>Global PhPID: 0xE857DA811B4A6F3BD57810C45D2EA1ED</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. 640921 MONURIL Granulaat 3000mg/8g in sachet</td>
</tr>
<tr>
<td>0xE857DA811B4A6F3BD57810C45D2EA1ED</td>
</tr>
<tr>
<td>2. 2940035 FOSFOMYCINE Focus granulaat 3000mg in sachet</td>
</tr>
<tr>
<td>0xE857DA811B4A6F3BD57810C45D2EA1ED</td>
</tr>
</tbody>
</table>

FCAT May 2022, FHIR 4.6.0
IMI Gravitate Health and HL7 Vulcan

► Gravitate-Health Consortium, part of the Innovative Medicines Initiative (IMI)
  ➢ 39 partners in Europe and USA
  ➢ 60 months 11/20 – 10/25; 18.5 mill €
  ➢ European start Global Outreach

► HL7 Vulcan - FHIR Accelerator Program
  ➢ Designed to facilitate the creation and adoption of FHIR Implementation Guides or other standards that support global health data interoperability.
What is interoperability?

- Ability to easily access and exchange information across systems.
- Ideal for technically different systems managed by different organizations.
- Common examples of international standards

Icons: Internet, Wifi, Email, Health, FHIR
What is Fast Healthcare Interoperability Resources (FHIR)?

- Standard for encoding and exchanging health data.
- Based on common internet standards (e.g., same tech foundation as Twitter, Amazon, Apple, Google).
- Significantly easier to work with and reduces implementation cost.
- 151 pre-fabricated, ready to use templates (e.g., Medicinal Product, Organization, Ingredient).
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299.
Example: Vulcan ePI on FHIR and IDMP

- **Bundle**
  - Composition
  - Organization
  - Regulated Authorization
  - Medicinal Product Definition
  - Administrable Product Definition
  - Manufactured Item Definition
  - Packaged Product Definition
  - Ingredient
  - Clinical Use Definition

- **FHIR resource for Organizations**
- **FHIR resource for Packaging**
- **FHIR resource for Ingredients**
- **FHIR resource for Clinical Use**
Adding a PhPID to the Vulcan ePI

- Substance, Strength, Unit of Measure, and Dosage Form are important terminologies since they are used to generate the Pharmaceutical Product Identifier (PhPID)
  - PhPIDs uniquely identify medicinal products by generic composition, separate from other details such as authorisation, organisation, packaging or trade name.
  - Example below: All 3 g Oral Solutions of fosfomycin have the same PhPID.
  - To facilitate search and data mining, PhPIDs (and their constituent IDs) are embedded in FHIR ePIs

```
Substance ID         +   Strength/Unit of Measure  +   Dose form        =   PhPID
7FXW6U30GY (Fosfomycin)  +     3 g                 +   10105000 (Oral solution)  =   0xE857DA811B4A6F3BD578 10C45D2EA1ED
IDMP Substance Standard      IDMP Unit of Measure Standard         IDMP Dosage Form Standard         IDMP Pharmaceutical Product Standard
```
Adding a PhPID to the Vulcan ePI

Monuril Leaflet

12.40.2 B. Package Leaflet

PACKAGE LEAFLET: INFORMATION FOR THE USER MONURIL 3g granules for oral solution. Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

12.40.3 What is in this leaflet

What is this leaflet?
1. What Monuril is and what it is used for
2. What you need to know before you take Monuril
3. How to take Monuril
4. Possible side effects
5. How to store Monuril
6. Contents of the pack and other information

12.40.4 1. What Monuril is and what it is used for

1. What Monuril is and what it is used for Monuril contains the active substance fosfomycin (as fosfomycin trometamol). It is an antibiotic that works by killing bacteria which can cause infections. Monuril is used to treat uncomplicated infection of the bladder in women and female adolescents. Monuril is used as antibiotic prophylaxis for transrectal prostate biopsy in adult men.

12.40.5 2. What you need to know before you take Monuril

2. What you need to know before you take Monuril Do not take Monuril if you:
• are allergic to fosfomycin or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions Talk to your doctor, pharmacist or nurse before using Monuril if you suffer from one of the following disorders:
• persistent infections of the bladder,
• previously had diarrhea after taking any other antibiotics.

Conditions you need to look out for

Monuril can cause serious side effects. These include allergic reactions and an inflammation of the large intestine. You must look out for certain symptoms while you are taking this medicine, to reduce the risk of any problems. See ‘‘Serious side effects’’ in Section 4.

Children and adolescents

Do not give the medicine to children less than 12 years of age, as its safety and efficacy have not been established in this age group.

Other medicines and Monuril
Use case example 1: Viewing Vulcan ePI as a graph

- Graphs showing ePI data and data relationships.
- This graph shows the 90+ data objects in a single ePI.
- Graphing a drug portfolio leads to benefits like rapid impact analysis of labelling changes (e.g., Safety updates, formulation, packaging).
Use case example 2: Focusing

Case:
- Highlight and suppress ePI sections based on patient information

Approach:
- Identifiable ePI sections from Felleskatalogen
- Manually extracted knowledge, coded by ICPC-2, linking sections, represented as FHIR ClinicalUseIssue
- Patient information, coded as ICPC-2, represented as FHIR AllergyIntolerance and Condition resources
- Demographic information
- Software for highlighting and suppressing text

Prepared
Petter Hurlen, AHUS
Knut Skifield, NeH
Gunvald Harket, NeH

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299
Navigating global and national identifiers using IDMP and HL7 FHIR

The Helen case: how the IPS and the ePI can work together
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299.

**Helen**

38 years old

- London, UK
- Diabetic type 1
- Business Lawyer
- Humalog Mix50

**Same foundation, two implementation models**

- **Common** Approach
  - All resources are contained in one bundle.
- **Same resources as the SPOR approach.**

---

**Example of Gravitate Basic G-lens focusing**

- Case: Display and highlight eFit sections based on patient information
- Approach:
  - Identifiable eFit sections from documentation
  - Manually extracted knowledge, coded by ICD-10 linking sections, represented as Fitail Clinicothetical
  - Patient information, coded as ICD-10, represented as Fitail Allergies
  - Demographic information
  - Software for highlighting and suppressing text

---

**EMEA’s SPOR Approach**

- Bundle cross-references out to SPOR
- Same resources as common approach.
The Helen case...

Helen has Diabetes Type 1 and therefore takes Humalog Mix50 daily.

View IPS

Patient Summary (Helen Gravitate)
- Summary Date: 2016-07-10T15:20:00-02:00
- Name: Helen, Gravitate

Allergies and Intolerances
- Critically: undefined
- Lactose (47030008)

Active problems / Diagnosis
- 2015 Diabetes mellitus type 1 (46635006) (Uncoded text shown): Diabetes type 1

Current Medications
- Humalog Mix50 (EU/1/96/007/035)
- Insulin lispro, 100 units/mL, suspension for injection (0x73A0F2EB22EA198B67635A8F83D6CA)
- Humalog Mix50 KatiPen 100 units/mL suspensions for injection 3 mL pre-filled pens (138B4911000000102)
- Insulin lispro (A10A0D4)
- Monauril (PL3169/0006)
- Fosfomycin, 3 g, Granules for oral solution (0x857DA811B4463D57810C45D2B8A1ED)
- Fosfomycin (J01X001)

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299
The Helen case.

Helen has Diabetes Type 1 and therefore takes Humalog Mix50 daily.

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>MAN</th>
<th>Active Substance</th>
<th>Common Name</th>
<th>ATC</th>
<th>Strength</th>
<th>Dose Form</th>
<th>RoA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humalog Mix50 100 units/ml suspension for injection in cartridge</td>
<td>EU/1/96/007/025</td>
<td>insulin lispro (GFX7QI511)</td>
<td>insulin lispro</td>
<td>A10AD04</td>
<td>100 U/ml</td>
<td>Suspension for injection</td>
<td>Subcutaneous use</td>
</tr>
</tbody>
</table>

**Medication Statement**

```
"resource": {  
"resourceType": "MedicationStatement",  
"id": "18eb9898-dea7-4c5e-b097-e507e011747b",  
"text": {  
"status": "generated",  
"div": "<div xmlns="http://www.w3.org/1999/xhtml">  
<table>  
<thead>  
<tr><th>Brand Name</th><th>MAN</th><th>Active Substance</th><th>Common Name</th><th>ATC</th><th>Strength</th><th>Dose Form</th><th>RoA</th>  
</tr>  
<tbody>  
<tr><td>Humalog Mix50 100 units/ml suspension for injection in cartridge</td><td>EU/1/96/007/025</td><td>insulin lispro</td><td>insulin lispro</td><td>A10AD04</td><td>100 U/ml</td><td>Suspension for injection</td><td>Subcutaneous use</td>  
</tr>  
</tbody>  
</table>  
</div>"  
},  
"status": "active",  
"medicationReference": {  
"reference": "urn:uuid:9d7be868-8264-4d94-ad04-ef04ecc92e50",  
"display": "Humalog Mix50 100 units/ml suspension for injection in cartridge"  
},  
"subject": {  
"reference": "urn:uuid:be61951b-44fc-4853-8822-f9d398193c50",  
"display": "Helen Gravitate"  
},  
"dosage": [  
{  
"route": {  
"coding": [  
{  
"code": "20066000",  
"system": "http://standardterms.edqm.eu",  
"display": "Subcutaneous use"  
}  
]  
}  
]  
}  
```

**Medication**

```
"resource": {  
"resourceType": "Medication",  
"id": "9d7be868-8264-4d94-ad04-ef04ecc92e50",  
"code": {  
"coding": [  
{  
"code": "EU/1/96/007/035",  
"system": "http://ema.europa.eu/fhir/marketingAuthorizationNumber",  
"display": "Humalog Mix50"  
}  
],  
"system": "http://ema.europa.eu/fhir/marketingAuthorizationNumber",  
"display": "Humalog Mix50"  
],  
"form": [  
{  
"coding": [  
{  
"code": "0x073AF2E5B92AE19E8B67635AFFB3D6CA",  
"system": "https://www.who-umc.org/phpid",  
"display": "insulin lispro, 100 units/ml, suspension for injection in cartridge"  
}  
]  
},  
"system": "http://ema.europa.eu/fhir/marketingAuthorizationNumber",  
"display": "Humalog Mix50"  
],  
"subject": {  
"reference": "urn:uuid:be61951b-44fc-4853-8822-f9d398193c50",  
"display": "Helen Gravitate"  
},  
"dosage": [  
{  
"route": {  
"coding": [  
{  
"code": "A10AD04",  
"system": "http://ema.europa.eu/fhir/marketingAuthorizationNumber",  
"display": "insulin lispro"  
}  
]  
}  
]  
}  
```

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299
ePI, Same foundation, two implementation models

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299
The Helen Case

Helen has Diabetes Type 1 and therefore takes Humalog Mix50 daily.

...in this case the IPS shows, next to the brand name, strength and dose form, the PhPID-L4 (0x073AF2E5B92AE19E8B67635AFFB3D6CA) of the Humalog Mix 50....

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299
The Helen case

Product Lookup

1. PhPID
2. MAN
3. PCID
4. GTIN (DCID)
5. ATC
6. Ingredient ID
7. Other identifiers
8. Other attributes

ePI Retrieval

1. MP identifier (0 .. *)
   - MPID
   Or
   - FHIR resource ID

1. List ePI
2. ePI

1. MP identifier (1 .. 1)
2. (language)
The Helen case

Gravitate Lens

MPD system

Product Lookup

ePI Retrieval

ePI system

1. FHIR
2. MAN
3. PID
4. GTIN (DGI)
5. ATC
6. Ingredient ID
7. Other Identifiers
8. Other attributes

1. MP Identifier (0..*)
   • MPID
   Or
   • FHIR resource ID

1. MP Identifier (1..1)
   2. Language

1. List ePI
2. ePI

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299
The Helen case

Helen has Diabetes Type 1 and therefore takes Humalog Mix50 daily.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299.
Time permitting ..some additional challenges ....

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299
The Helen case.... Helen has Diabetes Type 1 and therefore takes Humalog Mix50 daily.

SNOMED CT ?, ICDxx ?, ....
The Helen case....

Indications
Humalog and Insulin Lispro Injection are rapid-acting insulin analogs indicated to improve glycemic control in adults and children with diabetes mellitus. Humalog Mix75/25 and Humalog Mix50/50, and Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 are mixtures of intermediate-acting and rapid-acting insulin analogs indicated to improve glycemic control in patients with diabetes mellitus.
The Helen case...

<table>
<thead>
<tr>
<th>Name</th>
<th>Flags</th>
<th>Card.</th>
<th>Type</th>
<th>Description &amp; Constraints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ingredient</td>
<td>YU</td>
<td>DomainResource</td>
<td>An ingredient of a manufactured item or phrase + Role if an ingredient is noted as an allergy should be a code. If the substance is a Sub should be documented in that resource Elements defined in Ancestry: id, meta, integral, extension, modifierExtension</td>
<td></td>
</tr>
</tbody>
</table>

### Code:

- **Lactose monohydrate**

#### SNOMED CT ? ICD 10 (E73 “Lactose intolerance”)
Some challenges…

- Allergies: SNOmed CT: 47703008 "Lactose" ICD 10: E73 “Lactose intolerance”
  - UNII: J2B2A4N98G “LACTOSE,...”
  - (EU SPOR) SMS: 100000090052 “LACTOSE”

- Problems: SNOmed CT: 46635009 “Diabetes mellitus type 1" (or ICD–xx,...)
  - MedDRA: 73211009 “Diabetes mellitus”

- Medications: ATC; PhPID; GTIN, Other identifiers or identification attributes
  - MPID
How a Medicinal Product Dictionary supports Helen’s use case
What is an Medicinal Product Dictionary?

► ‘An MPD-system establishes a consistent representation of medication concepts (set of identifiers) at various levels of detail and with meaningful relationships between the concepts, in order to support use cases in healthcare in which medication plays a role.’

► Source: ISO TS 19256 Health informatics - Requirements for medicinal product dictionary systems for health care
Use cases of an MPD
structure of an mpd

- ideally: hierarchical or mirror structure with levels for:
  - substances
  - pharmaceutical product/
  - mpid/pcid

- ideally: connection with decision support, on the appropriate level of detail.
  - e.g. for allergy checking, drug-drug interactions, dose checking
National implementation of an MPD

- Local implementation of MPD necessary:
  - Prices of medicines
  - Reimbursement
  - Standardised extemporaneous preparations
  - etc
Existing MPD’s

- Drug data mostly based on:
  - Product information: MPID, PCID
  - Product information or SNOMED: substances, PhPID

- Local ID’s

To support the crossborder health services, a mapping between local ID’s and IDMP-ID’s is necessary
# Dutch PhP’s for fosfomycin

<table>
<thead>
<tr>
<th>Naam</th>
<th>GPK-code</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOSFOMYCINE POEDER V DRANK 3G</td>
<td>177490</td>
</tr>
<tr>
<td>FOSFOMYCINE INFUSIEPOEDER 4G</td>
<td>159506</td>
</tr>
<tr>
<td>FOSFOMYCINE GRANULAAT 3G</td>
<td>78735</td>
</tr>
</tbody>
</table>

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299
Dutch PhP for Monuril

GPK-gegevens

Farmaceutische vorm
- GRANULAAT

Toedieningsweg
- ORAAL

GPK-basiseenheid
- STUK

Werkzame stoffen (GSKw. 68330)

<table>
<thead>
<tr>
<th>Generieke naam</th>
<th>Hoeveelheid</th>
<th>Eenheid</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOSFOMYCINE TROMETAMOL</td>
<td>5.631</td>
<td>GRAM</td>
</tr>
</tbody>
</table>

Overige GPK-gegevens

Ingegeven sterke stofnamen
- 3G

ATC-code en-nam
- J01XX01

DDD (bij de ATC-code)
- 3 GRAM ORAAL
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875299

### G-Standaard hiërarchie

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SNK</td>
<td>41203</td>
<td>FOSFOMYCINE</td>
<td></td>
</tr>
<tr>
<td>SSK</td>
<td>48534</td>
<td>FOSFOMYCINE (ORAAL)</td>
<td></td>
</tr>
<tr>
<td>SPK</td>
<td>40649</td>
<td>FOSFOMYCINE (ORAAL)</td>
<td></td>
</tr>
<tr>
<td>GPK</td>
<td>78735</td>
<td>FOSFOMYCINE GRANULAAT 3G</td>
<td></td>
</tr>
<tr>
<td>PRK</td>
<td>30724</td>
<td>FOSFOMYCINE GRANULAAT 3G</td>
<td></td>
</tr>
<tr>
<td>HPK</td>
<td>640921</td>
<td>MONURIL GRANULAAT 3000MG/8G IN SACHET</td>
<td></td>
</tr>
<tr>
<td>ZI-nr</td>
<td>13722409</td>
<td>MONURIL GRANULAAT 3000MG/8G IN SACHET</td>
<td></td>
</tr>
<tr>
<td>ZI-nr</td>
<td>16257375</td>
<td>MONURIL GRANULAAT 3000MG/8G IN SACHET</td>
<td></td>
</tr>
<tr>
<td>HPK</td>
<td>2940035</td>
<td>FOSFOMYCINE FOCUS GRANULAAT 3000MG IN SACHET</td>
<td></td>
</tr>
<tr>
<td>ZI-nr</td>
<td>17003849</td>
<td>FOSFOMYCINE FOCUS GRANULAAT 3000MG IN SACHET</td>
<td></td>
</tr>
</tbody>
</table>
### Productsamenstelling

**Samenstelling per ST**

<table>
<thead>
<tr>
<th>Product</th>
<th>Quantity</th>
<th>G</th>
<th>W</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOSFOMYCINE (ALS TROMETAMOL)</td>
<td>3,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SACCHAROSE</td>
<td></td>
<td>H</td>
<td></td>
</tr>
<tr>
<td>SACCHARINE</td>
<td></td>
<td>H</td>
<td></td>
</tr>
<tr>
<td>MANDARIJNESSENCE</td>
<td></td>
<td>H</td>
<td></td>
</tr>
<tr>
<td>SINAASAPPELESSENCE</td>
<td></td>
<td>H</td>
<td></td>
</tr>
</tbody>
</table>
Artikelen

<table>
<thead>
<tr>
<th>ZI-nummer</th>
<th>13722409</th>
</tr>
</thead>
<tbody>
<tr>
<td>Artikelnaam</td>
<td>MONURIL GRANULAAT 3000MG/8G IN SACHET</td>
</tr>
<tr>
<td>GTIN</td>
<td>8717056280332</td>
</tr>
<tr>
<td>Inkoophoeveelheid</td>
<td>1 ST</td>
</tr>
<tr>
<td>Aantal deelverpakkingen</td>
<td>1 ZAKJE (SACHET)</td>
</tr>
<tr>
<td>Hoeveelheid per deelverpakking</td>
<td>1 ST</td>
</tr>
<tr>
<td>Inkoopprijs (excl. BTW)</td>
<td>€ 4,65</td>
</tr>
<tr>
<td>Vergoedingsprijs</td>
<td>€ 4,65</td>
</tr>
<tr>
<td>BTW-percentage</td>
<td>9 %</td>
</tr>
<tr>
<td>GVS clustercode</td>
<td>0G04ACBO V</td>
</tr>
<tr>
<td>GVS limiet</td>
<td>€ 2,28706</td>
</tr>
<tr>
<td>WTG code</td>
<td>1 (WMG artikel)</td>
</tr>
<tr>
<td>Kode wet op de geneesmiddelen</td>
<td>R (Uitsluitend op recept)</td>
</tr>
</tbody>
</table>
Thank you for listening!
Questions in the Q & A facility, please
For feedback, please go to :
https://docs.google.com/forms/d/e/1FAIpQLSdXBLIrWUmWigwRIHptlD6fD6zeSUkX8MpmLNRehGlkIS8FrQ/viewform?usp=pp_url

Thanks for your time
Questions, comments